Publicity Vzorová ustanovení

Publicity. Customer is permitted to state publicly that it is a customer of the Services, consistent with the Trademark Guidelines. If Customer wishes to display Google Brand Features or Revolgy Brand Features in connection with its use of the Services, Customer must obtain written permission from Google or Revolgy through the process specified in the Trademark Guidelines in relation to Google or by contacting Revolgy’s representative in case of Revolgy. Google and Revolgy may include Customer’s name or Brand Features in a list of Google customers or Revolgy customers, online or in promotional materials. Google and Revolgy may also verbally reference Customer as a customer of the Services. Neither party needs approval for repeating a public statement that is substantially similar to a previously approved public statement. Any use of a party’s Brand Features will inure to the benefit of the party holding Intellectual Property Rights to those Brand Features. A party may revoke the other party’s right to use its Brand Features under this Clause by giving written notice to the other party and allowing a reasonable period to stop the use.

Publicity. Neither party shall use the name of the other party in any publicity, advertising or announcement without the other party’s prior written approval. The foregoing restriction shall also apply to Provider of Medical Services’ and Principal Investigator’s use of the name and/or trademark of any third parties collaborating with AbbVie on the Study (“AbbVie Collaborators”). In accordance with the foregoing, Provider of Medical Services agrees, subject to the terms of Section 6 of the Agreement, to publish this Agreement in the Registry of Agreements at xxxxxxx.xxx.xx in accordance with the terms of 340/2015 Coll. Act on Register of Contracts (the “Act”) within five (5) business days of full execution of the Agreement and to promptly notify AbbVie of publication. Should Provider of Medical Services fail to publish this Agreement within thirty (30) days of fully execution of the Agreement, AbbVie reserves the right to publish this Agreement, after prior verification of its non- disclosure, as required under the Act. AbbVie and Provider of Medical Services hereby agree that: (i) Exhibit C attached hereto represents: (i) a redacted version of the Agreement, amended in accordance with the Act by removing all sections and exhibits which include confidential information, personal details and trade secrets; and (ii) the redacted Agreement attached hereto as Exhibit C shall be the version of the Agreement to be published in accordance with the Act. For purposes of clarity, exhibits such as the Budget, the Protocol, insurance certificates and information regarding patient reimbursement shall not be included in the redacted version of the Agreement to be published in accordance with the Act.

Publicity. Neither Party may use the other party’s name, any trademark, logo, or any other identifier of the other Party in any form of advertising, promotion, publicity, including press releases, or any other purpose, without the prior written consent of the other Party, nor shall either Party disclose the existence or substance of this Agreement or any Statement of Work except as required by law.

Publicity. Neither party shall use the name of the other party in any publicity, advertising or announcement without the other party’s prior written approval. In accordance with the foregoing, Provider of Medical Services agrees, subject to the terms of Section 7 of the Agreement, to publish this Agreement in the Registry of Agreements at xxxxxxx.xxx.xx in accordance with the terms of 340/2015 Coll. Act on Register of Contracts (the “Act”) within five (5) business days of full execution of the Agreement and to promptly notify AbbVie of publication. Should Provider of Medical Services fail to publish this Agreement within thirty (30) days of fully execution of the Agreement, AbbVie reserves the right to publish this Agreement as required under the Act. AbbVie and Provider of Medical Services hereby agree that: (i) Exhibit D attached hereto represents: (i) a redacted version of the Agreement, amended in accordance with the Act by removing all sections and exhibits which include confidential information, personal details and trade secrets; and (ii) the redacted Agreement attached hereto as Exhibit D shall be the version of the Agreement to be published in accordance with the Act. For purposes of clarity, exhibits such as the Budget, the Protocol, insurance certificates and information regarding subject reimbursement shall not be included in the redacted version of the Agreement to be published in accordance with the Act.

Publicity. Neither party shall use the name of the other party in any publicity, advertising or announcement without the other party’s prior written approval. The foregoing restriction shall also apply to Provider of Medical Services’ and Investigator’s use of the name and/or trademark of any third parties collaborating with AbbVie on the Study (“AbbVie Collaborators”). In accordance with the foregoing, Provider of Medical Services agrees, subject to the terms of Section 7 of the Agreement, to publish this Agreement in the Registry of Agreements at xxxxxxx.xxx.xx in accordance with the terms of 340/2015 Coll. Act on Register of Contracts (the “Act”) within five (5) business days of full execution of the Agreement and to promptly notify AbbVie of publication. Should Provider of Medical Services fail to publish this Agreement within thirty (30) days of fully execution of the Agreement, AbbVie reserves the right to publish this Agreement, after prior verification of its non-disclosure, as required under the Act. AbbVie and Provider of Medical Services hereby agree that: (i) Exhibit C attached hereto represents: (i) a redacted version of the Agreement, amended in accordance with the Act by removing all sections and exhibits which include confidential information, personal details and trade secrets; and (ii) the redacted Agreement údaje, osobní údaje a obchodní tajemství; a (ii) že redigovaná verze Smlouvy, zde připojená jako Příloha C bude představovat verzi této Smlouvy, která bude zveřejněna v souladu s příslušnými ustanoveními Zákona. Pro účely přesnosti a jasnosti, přílohy jako Rozpočet, Protokol, pojistné certifikáty a údaje týkající se pacientských náhrad nebudou obsaženy v redigované verzi Smlouvy, která bude podléhat zveřejnění na základě příslušných ustanovení Zákona. attached hereto as Exhibit C shall be the version of the Agreement to be published in accordance with the Act. For purposes of clarity, exhibits such as the Budget, the Protocol, insurance certificates and information regarding patient reimbursement shall not be included in the redacted version of the Agreement to be published in accordance with the Act.

Publicity. Neither Party will use the name of the other Party or the other Party’s employees or any of their trademarks in any advertising, sales promotional material, or press release without the other Party’s prior written approval, except to the extent such disclosure is reasonably necessary for: (i) regulatory filings, including filings with the U.S. Securities and Exchange Commission or the FDA (or any equivalent oversight body in a country other than the United States); (ii) prosecuting or defending litigation; and (iii) complying with applicable laws, rules, and regulations. Notwithstanding the foregoing, Sponsor may, without prior consent, publicly disclose information about Provider and Investigator as required by applicable law, including, but not limited to identifying Provider as the entity that is conducting the Trial, Investigator as conducting the Trial at Provider, and the amount of funding provided to Provider by Sponsor for the conduct of the Trial. Provider and Investigator consent to this disclosure. Provider and Investigator may, without prior consent, disclose in Provider’s confidential internal reports or governmental reports and grant applications, their participation in the Trial (including Sponsor’s name, the name of the Trial and Protocol number).

Publicity. Neither Party will use the name of the other Party or the other Party’s employees or any of their trademarks in any advertising, sales promotional material, or press release without the other Party’s prior written approval, except to the extent such disclosure is reasonably necessary for: (i) regulatory filings, including filings with the U.S. Securities and Exchange Commission or the FDA (or any equivalent oversight body in a country other than the United States); (ii) prosecuting or defending litigation; and (iii) complying with applicable laws, rules, and regulations. Notwithstanding the foregoing, Sponsor may, without prior consent, publicly disclose information about Institution and Investigator as required by applicable law, including, but not limited to identifying Institution as the entity that is conducting the Trial, Investigator as conducting the Trial at Institution, and the amount of funding provided to Institution by Sponsor for the conduct of the Trial. Institution and Investigator consent to this disclosure. Institution and Investigator may, without prior consent, disclose in Institution’s confidential internal reports or governmental reports and grant applications, their participation in the Trial (including Sponsor’s name, the name of the Trial (včetně názvu zadavatele, názvu klinického hodnocení a čísla protokolu) v důvěrných interních materiálech zdravotnického zařízení nebo zprávách pro státní orgány a v žádostech o grant.

Publicity. Neither party shall use the name of the other party in any publicity, advertising or announcement without the other party’s prior written approval. In accordance with the foregoing, Provider of Medical Services agrees to publish this Agreement in the Registry of Agreements at xxxxxxx.xxx.xx in accordance with the terms of 340/2015 Coll., Act on Register of Contracts, as amended (the “Act”) within ten

Filter & Search

Related Clauses

Parent Clauses